Answers are grounded in this paper and cite their sources.
EUS-RFA demonstrates long-term control in non-surgical patients with worrisome features, suggesting its efficacy as a therapy.
EUS-RFA is feasible, safe, and provides durable local control of BD-IPMNs with WF/HRS in patients unsuitable for surgery or declining resection. These results support EUS-RFA as a promising therapeutic option in carefully selected patients. Larger prospective studies are needed to refine selection criteria and confirm long-term oncologic benefit.
No takes yet. Share an insight, caveat, or question.
Barras et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: